The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials

Keyphrases

• Rheumatoid Arthritis 100%
• Meta-analysis 100%
• Comparative Safety 100%
• Odds Ratio 100%
• Tumour Necrosis Factor Inhibitor (TNFi) 100%
• Adalimumab 50%
• Certolizumab Pegol 50%
• Etanercept 50%
• Serious Infection 50%
• Confidence Interval 50%
• Infliximab 50%
• Adverse Events 50%
• Placebo 33%
• Randomized Controlled Trial 33%
• High Risk 33%
• Disease-modifying Antirheumatic Drugs (DMARDs) 33%
• Malignancy 16%
• Golimumab 16%
• Drug Treatment 16%
• Systematic Literature Review 16%
• Risk Estimation 16%
• Randomized Double-blind Controlled Trial 16%
• Safety Data 16%
• Low Dose Rate 16%
• Statistical Significance 16%
• Adverse Event Rates 16%
• Decreased Risk 16%
• Serious Adverse Events 16%
• Peto Odds Ratio 16%
• Discontinuation Rate 16%
• Treatment Discontinuation 16%
• Comparative Decision Making 16%
• Inhibitor Treatment 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Rheumatoid Arthritis 100%
• Tumor Necrosis Factor Inhibitor 100%
• Inflammatory Arthritis 100%
• Adverse Event 66%
• Infection 50%
• Infliximab 50%
• Etanercept 50%
• Adalimumab 50%
• Certolizumab Pegol 50%
• Randomized Controlled Trial 33%
• Placebo 33%
• Disease Modifying Antirheumatic Drug 33%
• Pharmacotherapy 16%
• Golimumab 16%